Results
|
|
1.
|
Low-Fat Dietary Pattern and Breast Cancer Mortality in the Women's Health Initiative Randomized Controlled Trial. MedStar authors:
Year: 2017
Citation: - Journal of Clinical Oncology. 35(25):2919-2926, 2017 Sep 01
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Anderson GL, Aragaki AK, Barrington W, Chlebowski RT, Hou L, Howard BV, Lane D, Manson JE, Prentice RL, Qi L, Rohan TE, Simon MS, Snetselar L, Thomas F, Thomson CA, Vitolins MZ, Womack C
|
|
|
2.
|
|
|
|
3.
|
Body Mass Index at Diagnosis and Breast Cancer Survival Prognosis in Clinical Trial Populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38. MedStar authors:
Year: 2016
Citation: - Cancer Epidemiology, Biomarkers & Prevention. 25(1):51-9, 2016 Jan.
Institution: - Washington Cancer Institute
Medline publication type:
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
All authors: - Anderson SJ, Cecchini RS, Costantino JP, Geyer CE Jr, Jeong JH, Lembersky BC, Paterson AH, Rastogi P, Romond EH, Swain SM, Tang G, Wolmark N
|
|
|
4.
|
Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. MedStar authors:
Year: 2012
Citation: - Lancet Oncology. 13(7):734-42, 2012 Jul.
Institution: - Washington Cancer Institute
Medline publication type:
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
All authors: - Anderson SJ, Baez-Diaz L, Brufsky AM, Costantino JP, Dakhil S, Falkson CI, Fehrenbacher L, Geyer CE Jr, Gralow JR, King KM, Lad T, Lembersky BC, Mamounas EP, Paterson AH, Perez EA, Robidoux A, Swain SM, Weir LM, Wolmark N, Zheng P
|
|
|
5.
|
Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. MedStar authors:
Year: 2014
Citation: - Journal of Clinical Oncology. 32(33):3744-52, 2014 Nov 20.
Institution: - Washington Cancer Institute
Medline publication type:
- Journal Article
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Colon-Otero G, Davidson NE, Geyer CE Jr, Gralow J, Jeong JH, Mamounas E, Martino S, Perez EA, Rastogi P, Romond EH, Sledge G, Suman VJ, Swain SM, Winer EP, Wolmark N, Zujewski JA
|
|
|
6.
|
Twenty-five year results of the national cancer institute randomized breast conservation trial. MedStar authors:
Year: 2012
Citation: - Breast Cancer Research & Treatment. 132(1):197-203, 2012 Feb.
Institution: - Washington Cancer Institute
Medline publication type:
- Journal Article
- Randomized Controlled Trial
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
All authors: - Camphausen K, Dan T, Danforth DN, Glatstein E, Lippman ME, Lita E, Sciuto L, Shih J, Simone NL, Smith SL, Swain SM
|
|
|
7.
|
Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA. MedStar authors:
Year: 2014
Citation: - Annals of Oncology. 25(6):1116-21, 2014 Jun.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Baselga J, Cortes J, Im YH, Lee LF, Miles D, Quah C, Swain SM
|
|
|
8.
|
Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA). MedStar authors:
Year: 2013
Citation: - Breast Cancer Research & Treatment. 142(1):89-99, 2013 Nov.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Amadori D, Baselga J, Clark E, Knott A, Miles D, Ross G, Semiglazov V, Sunpaweravong P, Swain SM
|
|
|
9.
|
Dietary Modification and Breast Cancer Mortality: Long-Term Follow-Up of the Women's Health Initiative Randomized Trial. MedStar authors:
Year: 2020
Citation: - Journal of Clinical Oncology. 38(13):1419-1428, 2020 05 01.
Institution: - MedStar Heart & Vascular Institute
Medline publication type:
All authors: - Anderson GL, Aragaki AK, Barac A, Chlebowski RT, Johnson KC, Lane DS, Luo J, Manson JE, Mossavar-Rahmani Y, Neuhouser ML, Pan K, Prentice RL, Rohan TE, Snetselaar L, Thomson CA, Wactawski-Wende J, Women's Health Initiative
|
|
|
10.
|
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. MedStar authors:
Year: 2015
Citation: - New England Journal of Medicine. 372(8):724-34, 2015 Feb 19.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Baselga J, Benyunes MC, Campone M, Ciruelos E, Clark E, CLEOPATRA Study Group, Cortes J, Ferrero JM, Heeson S, Kim SB, Ro J, Ross G, Schneeweiss A, Semiglazov V, Swain SM
|
|
|
11.
|
Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial. MedStar authors:
Year: 2013
Citation: - Journal of Clinical Oncology. 31(26):3197-204, 2013 Sep 10.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, N.I.H., Extramural
All authors: - Atkins JN, Azar CA, Biggs DD, Brufsky AM, Costantino JP, Donnellan PP, Fehrenbacher L, Geyer CE Jr, Levine EA, Mamounas EP, Northfelt DW, Paik S, Polikoff JA, Provencher L, Rastogi P, Robidoux A, Swain SM, Tang G, Wolmark N, Zapas JL
|
|
|
12.
|
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. MedStar authors:
Year: 2013
Citation: - Lancet Oncology. 14(6):461-71, 2013 May.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Baselga J, Benyunes MC, Campone M, Ciruelos E, Clark E, Cortes J, Ferrero JM, Kim SB, Knott A, Ro J, Ross G, Schneeweiss A, Semiglazov V, Swain SM
|
|
|
13.
|
Cardiometabolic risk factors and survival after cancer in the Women's Health Initiative. MedStar authors:
Year: 2021
Citation: - Cancer. 127(4):598-608, 2021 02 15.
Institution: - MedStar Heart & Vascular Institute
Medline publication type:
All authors: - Banack HR, Barac A, Beebe-Dimmer JL, Caan BJ, Chlebowski RT, Foraker R, Hastert TA, Hovsepyan G, Liu S, Luo J, Manson JE, Neuhouser ML, Okwuosa TM, Pan K, Qi L, Ruterbusch JJ, Shadyab AH, Simon MS, Thomson CA, Wactawski-Wende J, Waheed N
|
|
|
14.
|
Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. MedStar authors:
Year: 2012
Citation: - Journal of Clinical Oncology. 30(12):1268-73, 2012 Apr 20.
Institution: - Washington Cancer Institute
Medline publication type:
- Comparative Study
- Journal Article
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
All authors: - Allred DC, Anderson SJ, Costantino JP, Geyer CE Jr, Julian TB, Land SR, Mamounas EP, Nagtegaal ID, Paik S, Swain SM, Wickerham DL, Wolmark N
|
